Bio-Techne Corp (TECH)
| Market Cap | 19.68B |
| Revenue (ttm) | 931.03M |
| Net Income (ttm) | 140.41M |
| Shares Out | 38.91M |
| EPS (ttm) | 3.47 |
| PE Ratio | 143.52 |
| Forward PE | 59.88 |
| Dividend | $1.28 (0.26%) |
| Ex-Dividend Date | Aug 13, 2021 |
| Volume | 202,991 |
| Open | 497.97 |
| Previous Close | 497.85 |
| Day's Range | 496.12 - 503.48 |
| 52-Week Range | 249.40 - 543.85 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 549.60 (+10.4%) |
| Est. Earnings Date | Nov 4, 2021 |
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell sele...
Financial Performance
In 2021, Bio-Techne's revenue was $931.03 million, an increase of 26.04% compared to the previous year's $738.69 million. Earnings were $140.41 million, a decrease of -38.76%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for Bio-Techne stock is "Buy." The 12-month stock price forecast is 549.60, which is an increase of 10.36% from the latest price.
News
Bio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases
MINNEAPOLIS, Oct. 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Pro...
Bio-Techne To Host Conference Call On November 2, 2021 To Announce First Quarter 2022 Financial Results
MINNEAPOLIS, Oct. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021, at 8:00 a.m. CDT to...
REGN or TECH: Which Is the Better Value Stock Right Now?
REGN vs. TECH: Which Stock Is the Better Value Option?
Go Big or Go Home: The Best Ideas for Q4 from Piper Sandler's Craig Johnson
Piper Sandler chief market technician Craig Johnson shares some of his firm's best investing ideas for the rest of the year, including some under-the-radar names in the chemical and energy sectors.
Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPS...
Bio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis
MINNEAPOLIS and SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagno...
Techne (TECH) Soars to 52-Week High, Time to Cash Out?
Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bio-Techne To Present At The 2021 Virtual Wells Fargo Healthcare Conference
MINNEAPOLIS, Sept. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 Virtual Wells Fargo H...
Is Techne (TECH) a Solid Growth Stock? 3 Reasons to Think " Yes "
Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.
Bio-Techne Set to Join S&P 500; Saia, Mimecast & Option Care Health to Join S&P MidCap 400; Others to Join S&P SmallC...
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening of trading on Monday, Au...
Can Bio-Techne (TECH) Stock Continue to Grow Earnings?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Techne (TECH).
Techne (TECH) Q4 Earnings and Revenues Beat Estimates
Techne (TECH) delivered earnings and revenue surprises of 11.31% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bio-Techne Declares Dividend
MINNEAPOLIS, Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2021...
Bio-Techne Releases Fourth Quarter Fiscal 2021 Results
MINNEAPOLIS, Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2021. Fourth Quarter FY2021 Snapshot Fourth quar...
Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous te...
MINNEAPOLIS, Aug. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the impo...
Bio-Techne Announces 2021 Investor Day and Webcast
MINNEAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2021 Investor Day on Friday, September 10, 2021, starting at 9:00 a.m. EDT. ...
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Techne (TECH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Techne and PROGEN Introduce New Simple Plex AAV2 Immunoassay
MINNEAPOLIS, July 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for AAV2 total ...
Bio-Techne Announces Commercial Release of RNAscope™ HiPlex V2 Assay for Single Cell Validation and Spatial Transcrip...
MINNEAPOLIS, July 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope in situ hybridization ...
Why the Earnings Surprise Streak Could Continue for Techne (TECH)
Techne (TECH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ALXN vs. TECH: Which Stock Is the Better Value Option?
ALXN vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Bio-Techne To Host Conference Call On August 5, 2021 To Announce Fourth Quarter 2021 Financial Results
MINNEAPOLIS, July 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, August 5, 2021, at 8:00 a.m. CDT to ...
Bio-techne Announces Opening Of New Ireland Facility
MINNEAPOLIS, June 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Ireland facility located in Dublin. This new facility reflects Bio-Techne's commitm...
Top-Performing Stocks With High Quality and Low Capital Expenditures
As of Friday, GuruFocus' “High Quality, Low CapEx” model portfolio has returned approximately 15.69% in the year to date, outperforming the Standard & Poor's 500 index benchmark's return of approximatel...